Clinical and Molecular Study to Evaluate the Effect of the Pixel CO2 Laser (FemiLiftTM) for the Treatment of Vulvo-Vaginal Atrophy

Exclusion Criteria

• •1. Vaginal Health Index Score (VHIS) \< 5.
• •2. Active genital infection.
• •3. Vaginal bleeding which did not underwent evaluation.
• •4. Previous vulvar, vaginal or cervical dysplasia, within the last 2 years, or previous cancer.
• •5. Recurring urinary tract infection or recurring infection of genital herpes (≥ 3 episodes in the recent year).
• •6. Pelvic Organ prolapse (POP) \>II, according to the pelvic organ prolapse quantification system (POP-Q).
• •7. Serious systemic disease or any chronic condition that could interfere with study compliance.
• •8. Any local, systemic and/or chronic autoimmune infection.
• •9. Taken part in a clinical trial concerning VVA, within 30 days prior to the enrolment.
• •10. Allergy to lidocaine or tetracaine.
• •11. Genital skin disease that may interfere with the treatment (these subjects should be included/excluded according to the investigator's discretion).
• •12. Use of anticoagulants, within 5 days prior to enrolment.
• •13. Active positive HPV test.
• •14. Active positive HSV (Acute or actively present within the last 2 months).
• •15. Heavy smoker (\>1 pack of cigarettes a day)
• •16. Any disease or medication that may interfere with the wound healing/immune function.
• •17. Pregnancy / breast feeding.
• •18. Any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromise the subject safety.